iRhythm Technologies Faces Securities Class Action Lawsuit

Investors urged to file lead plaintiff applications by April 8 following FDA warning letter and share price drop.

Investors have until April 8, 2024, to file lead plaintiff applications in a securities class action lawsuit against iRhythm Technologies, Inc.
The lawsuit claims iRhythm and certain executives failed to disclose material information, violating federal securities laws.
iRhythm's shares fell $7.41 per share, or 6.1%, after disclosing receipt of a Warning Letter from the FDA on May 30, 2023.
The FDA's warning addressed deficiencies in the marketing and capabilities of iRhythm's Zio AT System.
Several law firms are reminding investors of the deadline and encouraging those who suffered losses to secure counsel.